secwatch.observer — SEC 8-K summary
======================================

Issuer:     CYPHERPUNK TECHNOLOGIES INC. (CYPH)
CIK:        0001509745
Form:       8-K
Filed at:   2024-11-13T23:59:59+00:00
Accession:  0001104659-24-117217
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Leap Therapeutics Q3 net loss $18.2M; DKN-01 CRC enrollment complete, data mid-2025
--------------------------------------------------------------------------------

- Net loss of $18.2M for Q3 2024, up from $13.7M YoY, driven by higher R&D expenses.
- R&D expenses $14.9M (vs $11.5M); G&A $2.9M (vs $3.3M); cash $62.8M at Sept 30, 2024.
- Completed enrollment (188 patients) in Part B of DeFianCe study (DKN-01 in CRC); initial data expected mid-2025.
- DisTinGuish study (GEJ/gastric) Part C follow-up ongoing; initial data late 2024 or early 2025.
- Initiated development of FL-501, an anti-GDF-15 antibody for cachexia; promising preclinical data.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1509745/000110465924117217/0001104659-24-117217-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1509745/000110465924117217/tm2428221d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-117217

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer